esketamine hydrochloride (Spravato) (Last Updated: Apr 30, 2021)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Spravato
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:
Indicated in combination with a SSRI or SNRI, for the treatment of major depressive disorder in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.